Tajikistan Foreign Regulatory Actions and Domestic Impact: Dual Entry Routes for Safety Information

1. Key takeaways

Through two parallel provisions, Tajikistan connects foreign regulatory actions directly into domestic decision making: Article 20(5) requires the supervisory authority, when making the four types of decisions on registration, re-registration, suspension and prohibition of use, to take into account vigilance and monitoring information obtained domestically and abroad; Article 21(1)(8) provides that information that other countries have prohibited or withdrawn medicines and medical products itself constitutes a statutory ground for withdrawal from circulation. GRZAN points out that the combined effect of these two provisions is that foreign safety events have a dual entry point in Tajikistan: they affect both access decisions and, independently, trigger withdrawal, so companies must manage safety information uniformly on a global basis.

2. Legal basis

3. Expert insights

Insight 1: Article 20(5) covers four types of administrative decisions, not withdrawal alone. The decision types listed in the provision are registration, re-registration, suspension and prohibition of use. This means that the influence of foreign information runs through the whole life cycle: at the access stage it affects the outcome of first registration; at the renewal stage it affects the outcome of re-registration; and after marketing it affects decisions on suspension and prohibition of use. Companies need to submit a complete account of global safety data at every one of these nodes.

Insight 2: Article 21(1)(8) makes foreign withdrawal information an independent withdrawal ground. The wording of the ground refers to receipt of information from other countries that products have been prohibited or withdrawn, and does not require that the information be independently verified within Tajikistan. The effect is that foreign withdrawal decisions are transmissible, and the local regulator may make a withdrawal decision without reopening a safety investigation of its own.

Insight 3: Article 20(5) together with Article 20(3) and (4) forms an evidentiary structure. Paragraph 3 requires companies to report proactively, paragraph 5 authorizes the authority to adopt foreign information, and paragraph 4 prescribes liability for concealment and incomplete submission. Taken together, the completeness of company reports and the completeness of foreign information cross-check each other, and a gap on either side can lead to an adverse determination.

Insight 4: the international cooperation provision of Article 46 provides the legal channel for the flow of information. The article confirms that Tajikistan carries out international cooperation in the field of medicines and medical products, which supplies the institutional basis for obtaining foreign regulatory information and confirms the enforceability of Article 20(5).

Insight 5: Article 26(3)(3) makes foreign manufacturers both the source and the object of the information flow. Foreign manufacturers and their authorized persons may import products for the purposes of expert review, state registration and clinical trials; this arrangement places foreign manufacturers under both the reporting obligation and the direct reach of regulatory information.

4. Practical recommendations

1. Build a unified global safety database. Under Article 20(5), consolidate safety events from all markets into a single working file, used jointly for registration, re-registration and withdrawal assessments in Tajikistan.
2. Establish an immediate trigger mechanism for foreign withdrawal information. Under Article 21(1)(8), any prohibition or withdrawal information from any market must trigger a local assessment and report within a set number of working days.
3. Submit a global safety data account proactively in re-registration dossiers. Under Article 20(5), re-registration is likewise a node for adopting foreign information; submit proactively rather than waiting for queries.
4. Make reporting completeness an internal performance indicator. Under Article 20(4), the liability for concealment and incomplete submission is compounded by the foreign information cross-check of Article 20(5).
5. Write a safety information synchronization obligation into the authorized representative agreement. Under Article 26(3)(3), define the responsibilities and deadlines for information transfer between the foreign manufacturer and the local authorized representative.

5. Verification checklist

• □ Confirmed that Article 20(5) covers the four types of decisions on registration, re-registration, suspension and prohibition of use
• □ Confirmed that Article 21(1)(8) lists foreign prohibition or withdrawal information as an independent withdrawal ground
• □ Established a globally unified safety information database
• □ Established a trigger mechanism for local assessment of foreign withdrawal information
• □ Included a global safety data account in re-registration dossiers
• □ Made reporting completeness part of internal performance assessment (Article 20(4))
• □ Agreed on a safety information synchronization obligation in the authorized representative agreement (Article 26(3)(3))

Regulatory information verified as of October 29, 2026.

In the Central Asia market, the core capabilities of GRZAN concentrate on three points. First, distinguishing the different legal positions of individual markets within the Eurasian Economic Union — Kazakhstan and Kyrgyzstan are full member states, where a national pathway and a Union pathway both exist; Uzbekistan is an observer state with only a national pathway; Tajikistan and Turkmenistan lie outside the Union framework and must proceed entirely under national procedures. Second, local authorized representative services, which may act as the statutory representative of manufacturers in these countries and assume registration submissions, regulatory communication and post-market reporting obligations. Third, quality system and testing support, assisting in establishing a quality management system that meets ISO 13485 requirements and connecting with locally accredited laboratory resources.

Business inquiries: info@grzanglobal.com